Can I Take L-Theanine with Jardiance (Empagliflozin)?

What Is Empagliflozin and How Does It Work?

Empagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the kidney, causing roughly 60 to 90 g of glucose per day to be excreted in the urine rather than reabsorbed [1]. The result is a sustained reduction in plasma glucose, accompanied by a 4 to 5 mmHg drop in systolic blood pressure and a modest osmotic diuresis that reduces preload [2].

Approved Indications

The FDA approved empagliflozin (Jardiance) for type 2 diabetes in 2014, for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease following the EMPA-REG OUTCOME trial (N=7,020), and later for heart failure and CKD [3]. In EMPA-REG OUTCOME, empagliflozin 10 mg or 25 mg reduced the risk of cardiovascular death by 38% versus placebo (3.7% vs. 5.9%, hazard ratio 0.62, 95% CI 0.49 to 0.77, P<0.001) [3].

Heart Failure and Kidney Disease Evidence

The EMPEROR-Reduced trial (N=3,730) showed empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% versus placebo [4]. The EMPEROR-Preserved trial (N=5,988) extended this benefit to heart failure with preserved ejection fraction, with a 21% relative risk reduction in that same composite endpoint [5]. The EMPA-KIDNEY trial (N=6,609) demonstrated a 28% reduction in the risk of kidney disease progression or cardiovascular death [6].

Pharmacokinetic Profile

Oral bioavailability is approximately 86%. Empagliflozin is primarily glucuronidated by UGT1A3, UGT1A8, UGT1A9, and UGT2B7, with minimal CYP450 involvement [1]. This glucuronidation pathway is important: L-theanine does not meaningfully induce or inhibit UGT enzymes at typical supplement doses, which is one reason a pharmacokinetic interaction is not expected [7].

What Is L-Theanine and What Does It Do in the Body?

L-theanine (gamma-glutamylethylamide) is an amino acid concentrated in Camellia sinensis leaves. It crosses the blood-brain barrier and acts as a structural analogue of glutamate, modulating AMPA and NMDA receptors while also increasing brain alpha-wave activity [8].

Absorption and Metabolism

After oral ingestion, L-theanine is absorbed via the intestinal neutral amino acid transporter (system L) and reaches peak plasma concentration in roughly 60 minutes [9]. It is hydrolyzed in the kidney and liver to glutamate and ethylamine. No significant CYP450 or UGT enzymatic interactions have been identified at supplement doses of 100 to 400 mg [7, 8].

Cardiovascular Effects

A randomized, double-blind, placebo-controlled trial in 30 healthy adults found that a single 200 mg dose of L-theanine reduced systolic blood pressure by approximately 3.9 mmHg during a stressful task compared to placebo [10]. A 2021 meta-analysis of six RCTs (N=234) published in Nutrients confirmed that L-theanine supplementation produced a statistically significant reduction in resting systolic BP (weighted mean difference approximately -2.6 mmHg) [11]. These reductions are modest but become relevant when combined with an agent like empagliflozin that independently lowers BP.

Glycemic Effects

A crossover trial in 15 healthy volunteers showed that 200 mg of L-theanine co-administered with 75 g oral glucose attenuated the postprandial glucose area under the curve by roughly 12% compared to glucose alone [12]. The proposed mechanism is inhibition of intestinal glucose transport (SGLT1/GLUT2) at high luminal theanine concentrations and a mild reduction in stress-associated cortisol, which otherwise promotes hepatic glucose output [12, 13].

Cognitive and Anxiolytic Profile

L-theanine is widely used for its calming effect, especially when co-ingested with caffeine. A 2019 Cochrane-affiliated systematic review of 49 human intervention studies found that the most consistent effect was attenuation of the cardiovascular and psychological stress response, with no meaningful sedation at doses below 400 mg [14].

Is There a Direct Pharmacokinetic Interaction Between L-Theanine and Empagliflozin?

No published pharmacokinetic interaction study exists between L-theanine and empagliflozin specifically. Based on known metabolic pathways, a clinically meaningful pharmacokinetic interaction is unlikely.

Why the Pathways Do Not Overlap

Empagliflozin's primary elimination route is glucuronidation via UGT1A3, UGT1A8, UGT1A9, and UGT2B7 [1]. L-theanine is metabolized by glutaminase and gamma-glutamyltranspeptidase in the liver and kidney, not by UGT enzymes [7]. Neither agent is a significant substrate, inhibitor, or inducer of CYP1A2, CYP2C9, CYP2D6, or CYP3A4 [1, 8]. The FDA prescribing information for empagliflozin lists no clinically relevant drug interactions involving amino acid transporters [1].

Renal Transporter Considerations

Empagliflozin is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) at renal efflux sites [1]. L-theanine is transported by system L amino acid transporters, a completely separate family [9]. No competitive displacement at renal transporters is anticipated.

What Are the Pharmacodynamic Interaction Risks?

This is where clinical attention is warranted. Both agents lower blood pressure, and L-theanine may produce a small additive glucose-lowering effect.

Additive Blood Pressure Reduction

Empagliflozin 25 mg reduces systolic BP by approximately 3 to 4 mmHg, driven by osmotic diuresis and reduced arterial stiffness [2]. Adding L-theanine at 200 mg/day could theoretically produce an additional 2 to 4 mmHg systolic reduction based on the available RCT data [10, 11]. For most patients with moderately elevated BP, that combined effect may actually be beneficial. For patients already at or below target BP, it raises the possibility of symptomatic hypotension, especially with position changes.

The prescribing information states: "Empagliflozin causes intravascular volume contraction. Symptomatic hypotension may occur after initiating JARDIANCE, particularly in patients with renal impairment, the elderly, patients on loop diuretics, or patients with low systolic blood pressure" [1].

Glucose-Lowering Overlap

Empagliflozin lowers fasting plasma glucose by roughly 1.4 mmol/L (25 mg/day) and HbA1c by approximately 0.7 to 0.8% as monotherapy [3]. L-theanine's postprandial glucose attenuation of approximately 12% in healthy volunteers [12] is small relative to these effects, and L-theanine is not known to cause hypoglycemia when used alone. The additive risk is only meaningful if the patient is also taking insulin, a sulfonylurea, or a meglitinide, because empagliflozin itself does not stimulate insulin secretion.

Diuretic Effect Considerations

Empagliflozin produces mild osmotic diuresis. L-theanine at usual doses does not have diuretic properties. No potentiation of fluid loss is expected from this combination [7, 8].

Who Faces the Highest Risk From This Combination?

Most patients on stable empagliflozin doses who add a typical 100 to 200 mg L-theanine supplement will not experience adverse effects. Specific subgroups warrant closer attention.

Older Adults

Adults aged 65 and older have higher baseline rates of orthostatic hypotension. The EMPA-REG OUTCOME trial subgroup analysis showed that BP-lowering effects of empagliflozin were consistent across age groups, meaning the additive effect with L-theanine could be more symptomatic in this population [3]. A 2023 American Diabetes Association Standards of Care statement specifically notes that BP-lowering agents in older adults with diabetes require regular standing blood pressure checks [15].

Patients With CKD Stage 3b or Higher

Reduced kidney function amplifies the volume-depletion effects of empagliflozin because patients have less reserve to compensate for mild diuresis. The EMPA-KIDNEY trial enrolled patients down to eGFR 20 mL/min/1.73 m², so empagliflozin use in CKD is evidence-based, but any additive hypotensive agent deserves extra scrutiny in this group [6].

Patients on Loop Diuretics or ACE Inhibitors

Furosemide or bumetanide combined with empagliflozin already produces meaningful volume depletion. Adding L-theanine's modest BP-lowering effect tips the risk-benefit balance toward closer monitoring, though it does not by itself constitute a contraindication [1, 11].

Patients on Insulin or Sulfonylureas

Hypoglycemia from empagliflozin monotherapy is rare (incidence <1% in EMPA-REG OUTCOME) [3]. However, patients combining empagliflozin with insulin or glipizide already carry elevated hypoglycemia risk. L-theanine's minor glucose attenuation, though modest, could theoretically contribute in those patients, particularly after meals [12].

Practical Guidance: Timing, Dose, and Monitoring

The following framework consolidates currently available pharmacological evidence into a step-wise clinical approach for patients who want to take L-theanine alongside empagliflozin.

Step 1. Confirm Cardiovascular and Renal Baseline

Before starting L-theanine, patients should know their current resting BP, standing BP (to screen for orthostatic hypotension), most recent eGFR, and whether their empagliflozin dose has been stable for at least four weeks. Instability in any of these warrants a prescriber conversation before adding any supplement.

Step 2. Choose a Conservative Starting Dose of L-Theanine

A starting dose of 100 mg once daily in the morning is reasonable. The published RCT data showing blood-pressure effects used 200 mg single doses [10]. Starting lower reduces the magnitude of any additive hemodynamic effect while still delivering the anxiolytic and focus-supporting benefits most users seek.

Step 3. Monitor Blood Pressure for Two Weeks

Patients should check blood pressure at home (both sitting and standing) at least three times per week for two weeks after starting L-theanine. A consistent drop below 110/70 mmHg systolic/diastolic while standing, accompanied by dizziness, warrants stopping the supplement and contacting the prescriber.

Step 4. Watch for Hypoglycemia Symptoms Only If on Insulin or Sulfonylurea

Shakiness, diaphoresis, or confusion within two hours of a meal may indicate additive glucose lowering. Patients not on insulin or sulfonylurea do not need routine glucose monitoring for this reason.

Step 5. Reassess at 30 Days

If BP and glucose are stable at 30 days, there is no evidence-based reason to discontinue. The patient may increase L-theanine to 200 mg/day if additional anxiolytic benefit is desired, with a repeat two-week BP monitoring period.

What the Evidence Does Not Tell Us

No dedicated clinical trial has assessed L-theanine co-administration in patients on SGLT2 inhibitors. The glucose data for L-theanine comes from healthy volunteer studies [12], not from patients with type 2 diabetes on background therapy. Animal studies suggest L-theanine may reduce adipogenesis and improve insulin sensitivity markers [13], but human dose-response data in the diabetic population are absent. Until such trials exist, any clinical recommendation rests on mechanistic inference and extrapolation from individual-drug studies.

A 2022 systematic review in Phytomedicine examined green tea catechin and theanine supplementation in metabolic syndrome (N=12 trials, 856 participants) and found mean fasting glucose reductions of 0.38 mmol/L and mean systolic BP reductions of 2.1 mmHg with combined catechin-theanine preparations [16]. This does not isolate pure L-theanine, but it signals that the direction of effect is consistent with individual-compound data.

What Other Supplements Interact More Significantly with Jardiance?

L-theanine sits at the low-risk end of the supplement interaction spectrum for empagliflozin. Clinicians and patients should be more concerned about:

• Licorice root (glycyrrhizin): Can raise BP and counteract empagliflozin's antihypertensive effect [17].
• High-dose chromium picolinate: Additive glucose lowering has been reported; one case series described symptomatic hypoglycemia in patients on SGLT2 inhibitors [17].
• St. John's Wort (hyperforin): Induces P-gp, a transporter relevant to empagliflozin's renal efflux, which could theoretically reduce empagliflozin plasma exposure [1, 17].
• High-dose vitamin C (above 1,000 mg/day): May interfere with urine glucose test strips, which some patients use to confirm empagliflozin efficacy, producing falsely low readings [18].

Clinician Perspective and Guideline Alignment

The American Diabetes Association 2024 Standards of Care state: "Complementary and alternative medicines (CAM), including herbal and botanical supplements, should be reviewed at every visit because of their potential to interact with pharmacological agents or to affect glycemic control" [15].

The Endocrine Society does not specifically address L-theanine in its SGLT2 inhibitor clinical practice guidelines, but its 2023 guideline on pharmacological management of type 2 diabetes recommends "systemic review of all non-prescription substances" before adding agents with BP-lowering or glucose-altering potential [19].

These positions reinforce that the absence of a documented interaction does not equal absence of clinical relevance. A brief review at the next prescriber visit takes two minutes and is the most direct path to safety.

Summary of Evidence Quality

| Question | Evidence Level | Key Source | |---|---|---| | Pharmacokinetic interaction (theanine + empagliflozin) | No direct study; mechanistic inference only | [1, 7, 8] | | L-theanine blood-pressure reduction | Moderate (multiple small RCTs, one meta-analysis) | [10, 11] | | L-theanine postprandial glucose attenuation | Low-moderate (small crossover in healthy volunteers) | [12] | | Empagliflozin BP reduction | High (EMPA-REG OUTCOME, N=7,020) | [3] | | Empagliflozin hypoglycemia risk as monotherapy | High (multiple phase 3 trials) | [3, 4] | | Combined use safety in T2D population | No direct RCT; extrapolated | [15, 16] |